1. Population pharmacokinetics and pharmacodynamics of IONIS-GCGR_Rx, an antisense oligonucleotide for type 2 diabetes mellitus: a red blood cell lifespan model

   • Kenneth T. Luu
   • Erin S. Morgan
   • Yanfeng Wang

   Original Paper 28 January 2017 Pages: 179 - 191

   

2. Empirical models for fitting of oral concentration time curves with and without an intravenous reference

   • Michael Weiss

   Original Paper 01 February 2017 Pages: 193 - 201

   

3. Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments

   • Robert Andersson
   • Tobias Kroon
   • Johan Gabrielsson

   Original Paper Open access 21 February 2017 Pages: 203 - 222

   

4. Nonlinear mixed-effects models for pharmacokinetic data analysis: assessment of the random-effects distribution

   • Reza Drikvandi

   Original Paper 13 February 2017 Pages: 223 - 232

   

5. Comparison of non-compartmental and mixed effect modelling methods for establishing bioequivalence for the case of two compartment kinetics and censored concentrations

   • Jim H. Hughes
   • Richard N. Upton
   • David J. R. Foster

   Original Paper 13 February 2017 Pages: 233 - 244

   

6. Exposure–response analyses of blood pressure and heart rate changes for methylphenidate in healthy adults

   • Liang Li
   • Yaning Wang
   • Hao Zhu

   Original Paper 18 February 2017 Pages: 245 - 262

   

7. Exposure–disease response analysis of natalizumab in subjects with multiple sclerosis

   • Kumar Kandadi Muralidharan
   • Deb Steiner
   • Ivan Nestorov

   Original Paper 01 March 2017 Pages: 263 - 275

   

8. Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability

   • Paul R. V. Malik
   • Abdullah Hamadeh
   • Andrea N. Edginton

   Original Paper 04 March 2017 Pages: 277 - 290